NIA Payline 2026: No Cutoff, 5.0% New R01 Odds

Every institute's current rules and odds sit side by side in the NIH and NSF funding odds tracker.

NIA Payline 2026: Why There's No Number to Find

NIA's new R01 success rate was 5.0% in FY2025, and the institute hasn't replaced its old cutoff table with anything numeric. NIA's former payline web address now redirects to its FY2026 funding policy (opens in a new tab), which says each application "is assessed on a case-by-case basis" and that the listed factors "are not weighted or in priority order." Those factors are peer review, fit with NIA and NIH priorities, the PI's existing NIH support, career stage (ESI, new investigator, at-risk), geographic balance and available money.

Two NIH-level changes sit behind that page. NIH's funding decisions page (opens in a new tab), updated November 21, 2025, says institutes "will no longer employ these cutoff points in overall impact scores to determine which applications to fund." NIA's September 2025 Council minutes (opens in a new tab) put it the same way for NIA: fixed percentile paylines, once used by roughly half of NIH's institutes, "would no longer serve as the primary determinant of funding decisions."

NIH is also operating under a continuing resolution for FY2027 (NOT-OD-26-131), and NIA says it usually pays non-competing grants at 90% under a CR. So the honest answer to "NIA payline 2026" is that none exists, and any number you find on a forum is a guess or an old table.

The Last Published NIA Paylines: FY2024

NIA's FY2024 paylines split applications by a $500,000 direct-cost line, by AD/ADRD status and by investigator stage. According to NIA's September 2024 Council minutes (opens in a new tab), these were the FY2024 cutoffs for applications reviewed by NIH's Center for Scientific Review (CSR):

For applications NIA reviewed itself, the minutes tie paylines to priority scores instead: 25 for program projects, other NIA-reviewed research and career development awards, and 30 for fellowships. NIA-reviewed AD/ADRD paylines were 25 for program projects and research, 30 for career development and 35 for fellowships.

Treat this table as history. Grantsights checked the later Council minutes and NIA blog posts for a newer table. NIA's October 2024 blog said FY2025 would bring "very conservative interim pay lines" for both AD/ADRD and general applications, and Grantsights found no official final FY2025 NIA payline in any NIA source. A common mistake is reading the FY2024 table as a current target. The FY2025 success rates below show why that fails.

NIA R01 Success Rates, FY2021 to FY2025

NIA's new R01 success rate fell from 13.7% to 5.0% in a single year. NIH's success-rate tables (opens in a new tab) show the full five-year run:

Source: NIH Data Book table 206 for R01 rows and table 217 for all research project grants. Both sides of the ratio moved. New R01 applications rose 31% in one year, from 2,774 to 3,645, while awards fell by more than half. Renewals didn't escape: NIA funded 16 of 148 competing renewals in FY2025, against 41 of 127 a year earlier.

The smaller mechanisms dropped too. According to NIH Data Book table 206, NIA's R21 rate fell from 16.7% in FY2024 to 6.7% in FY2025 (107 of 1,593), and its R03 rate fell from 19.9% to 11.3%. R56 bridge awards went from 42 to 8. Combined R01 and R37 funding fell from $395.0 million to $194.8 million, while the average award rose slightly, from $929,306 to $945,604.

NIH counts an application and its resubmission in the same fiscal year once, under its success rate definition (opens in a new tab). These are application odds, not PI odds, and a PI who submits twice a year sees a better personal rate than the table shows.

The 16% Average Cut and Who's Exempt

NIA expects to reduce competing awards by 16% on average. Its FY2026 policy exempts:

• R03 small grants
• R21 exploratory and developmental awards
• R15 AREA and REAP awards
• R36 dissertation awards
• applications from new investigators and early stage investigators

Individual awards can be cut by more or less than 16% case by case. NIA's March 2024 budget blog said the FY2024 non-AD/ADRD reduction was also 16%, unchanged from FY2023, so this isn't a new emergency measure. It's the standing NIA practice.

The policy adds two more budget rules. Inflationary increases for future years aren't allowed, including salary escalation, so any year-over-year increase needs a non-inflationary reason stated in the justification. And NIA may apply out-year adjustments, uniform reductions across an activity code, or mid-project no-cost extensions when appropriations are tight.

Applicants often underestimate the cut when they plan staffing. A $500,000 direct-cost request reduced by 16% becomes $420,000, and the aims still have to fit. Build the budget so the core aims survive that reduction, and say which aim would shrink first. The modular budget guide covers how to build and justify each budget level.

Large Budgets: The $2 Million Contact Rule

NIA asks for early contact on any application requesting $2 million or more in direct costs in a single project year. The policy "strongly encourages" applicants to reach a program officer early, "preferably at least 8–12 weeks before submission," because the request affects NIA's budget planning. It isn't a formal prior-approval requirement, but skipping the call is a red flag on an application that big.

The same page says NIA rarely funds P01 program projects above $2 million in annual direct costs, and it reserves U19 cooperative agreements for projects whose components can't stand alone. The FY2024 table above also shows the old budget penalty: above $500,000 in direct costs, the general payline dropped from the 16th to the 13th percentile. That table is retired, but the signal behind it (bigger requests face a higher bar) still matches the case-by-case policy.

AD/ADRD Money Is a Separate Pot

Congress gives NIA a separate appropriation for Alzheimer's disease and related dementias, and NIA's March 2024 blog said AD/ADRD researchers had "benefited from a high payline (up to 28%) in the past years." The FY2026 policy says AD/ADRD applications meet the same merit standard but are "evaluated and funded within the context of this dedicated appropriation."

The practical test is NIA's AD/ADRD Research Implementation Milestones. The policy names alignment with those milestones, "especially those that have not yet been fully achieved," as a key consideration. If your project genuinely addresses a dementia question, say so in the specific aims and map it to a named milestone. If the AD/ADRD link is a single sentence added late, reviewers and program staff will notice, and it won't move you into the other pot.

NIA also gets a separate HIV allocation from the NIH Office of AIDS Research for HIV and aging research. That's a narrower route, but it's worth naming if your work fits.

RF1 Awards: Why a 97.7% Success Rate Isn't Real Odds

NIH Data Book table 206 shows NIA funded 84 of 86 RF1 applications in FY2025, a 97.7% rate, and 61 of 61 in FY2024. Those numbers aren't odds. NIA issues RF1 awards to applications it has already chosen to multi-year fund, which pays several years of a project in one fiscal year. By the time an application is counted in the RF1 row, the funding decision has effectively been made.

Grantsights analysis of these RePORTER records shows FY2025's RF1 count was the highest of the three years, and each award used a multi-year block of money. Grantsights can't say how NIA divided its FY2025 budget, but RF1 awards draw on the same appropriation as R01s, so a year with more multi-year blocks leaves less for new single-year awards. NIH's FY2025 by-the-numbers post (opens in a new tab) says NIH-wide changes "were likely due in part to more awards being forward funded than previous years." In FY2026, new RF1 records fell to 33, and NIH's FY2026 fiscal policy notice (opens in a new tab) sets the rules for multi-year funding this year.

NIA's FY2026 Award Record So Far

A Grantsights pull of NIH RePORTER (opens in a new tab) on November 8, 2026 found 467 new NIA R01 and R37 award records for FY2026, against 191 in FY2025 and 371 in FY2024. Only 2 of the FY2026 records were multi-year funded. For example, UCSF received 14 new NIA R01 and R37 awards in FY2026, tied with Columbia University Health Sciences, and California led all states with 71.

The FY2026 rebound is real in award counts, but it isn't a success rate. NIH hasn't published FY2026 application counts, and NIA's FY2025 application pool (3,645 new R01s) was the largest in the table. RePORTER counts also differ slightly from the Data Book because they include R37s and count award records.

Two details stand out. The FY2026 median first-year direct cost dropped to $442,075, from $492,691 in FY2025. And timing bunched late: 144 FY2026 notices went out in September and 123 in August, so 267 of 467 arrived in the last two months of the fiscal year. A quiet spring isn't a rejection.

Career and Fellowship Odds at NIA

NIA's K99 success rate fell from 22.3% in FY2024 to 7.8% in FY2025, and most training mechanisms followed. According to NIH Data Book tables 203 and 204:

K08 held steady, though on small numbers. For a postdoc choosing between a K99 and a later R01, NIA's FY2025 K99 rate (7.8%) was barely above its new R01 rate (5.0%), so neither was an easy route that year. Compare NIA's fellowship odds with other institutes in the F31 success rate by institute data and the K award success rates page.

What NIA's Policy Page Doesn't Tell You

NIA's May 2025 Council minutes report 3,311 applications reviewed and 1,698 recommended for funding, a recommendation rate above 50%. Council recommendation isn't funding. The minutes themselves say "the actual funding of the awards recommended is determined by the availability of funds, percentile ranks, priority scores, and program relevance," so a Council recommendation doesn't mean an award is coming. The September 2024 round showed the same gap, with 2,636 reviewed and 1,399 recommended.

The policy page also doesn't say how ESI status now translates into odds. In FY2024 the ESI R01 payline sat 9 points above the general one (25th against 16th). The FY2026 page lists ESI status as a factor and exempts ESI awards from the 16% cut, which is real protection, but it publishes no ESI number. Confirm your ESI flag in eRA Commons before review; the new investigator guide covers how.

Resubmit, Rebudget, or Wait: Next Action Table

NIA's 5.0% new R01 rate in FY2025 means most good applications missed. The question is what to change.

Before the A1, read the summary statement guide and the resubmission guide, and check how percentiles work in the NIH score explainer. For how other institutes set FY2026 rules without a cutoff, compare the NCI payline and NIDDK payline pages. To find aging-research funding beyond NIA, use Grantsights grant search.

Sources

• NIA FY2026 funding policies and considerations (opens in a new tab)
• NIA Council minutes, September 2024 (opens in a new tab) (FY2024 paylines)
• NIA Council minutes, May 2025 (opens in a new tab)
• NIA Council minutes, September 2025 (opens in a new tab)
• NIA blog, 2024 budget and paylines update (opens in a new tab)
• NIA blog, preparing for a tighter budget scenario (opens in a new tab)
• NIH funding decisions and the Unified Funding Strategy (opens in a new tab)
• NIH Data Book success-rate tables (opens in a new tab) (tables 203, 204, 206 and 217)
• NIH success rate definition (opens in a new tab)
• NIH, Fiscal Year 2025 By the Numbers (opens in a new tab)
• NOT-OD-26-059, fiscal policies for FY2026 (opens in a new tab)
• NIH RePORTER (opens in a new tab)

Related Guides

• NIH paylines explained
• NIH R01 grant success rate data
• NINDS payline
• NIH new investigator guide
• NIH K99/R00 winners and award history